From: From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience
Study | Centre | Number of patients | Median age (years) | FIGO IB2 (%) | FIGO II (%) | FIGO III (%) | FIGO IV (%) | Pelvic LNI (%) | Lombo aortic LNI (%) | Median/Mean follow-up (months) | DFS % (CI 95%) | OS % (CI 95%) | DSS % (CI 95%) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Present study | Saint Etienne, France | 94 | 63 | 10.6 | 73.3 | 16 | 0 | 34.1 | 0 | 43.9/54.3 | 56.7 (46.9–68.5) | 61.9 (52.3–73.2) | 68.5 (59.2–79.2) |
Sturdza, [6] | International cohort | 731 | 53 | 16.8 | 55.9 | 22.9 | 3.1 | 40.5 | 43 | 65 | – | 73 | |
Touboul, [5] | Villejuif, France | 150 | 47 | 32 | 61 | 7 | 0.7 | 32.7 | 0.7 | −/43.2 | 66 (57–74) | 71 (61–78) | – |
Haie-Meder, [8] | Villejuif, France | 84 | 46.5 | 23.8 | 44 | 26.2 | 6 | 36.9 | 53/− | 57* (43–69) | 52* (40–64) | – | |
Han, [21] | Toronto, Canada | 7359 | 55 (mean) | 8.2 | 52.5 | 35.8 | 3.5 | – | – | 40.8/− | – | 58.2* (with brachytherapy), 46.2* (without) | 64.3* (with brachytherapy), 51.5* (without) |
Magne, [14] | Villejuif, France | 113 | 76 | 3.5 (31% IA and IB1) | 45,1 | 16,8 | 3.6 | 14.2 | 6.2 | 37.2/− | 81** (72–88) | 88.6** (77–92) | – |
Gouy, [7] | Villejuif, France | 237 | 46 | 33 | 55 | 10 | 2 | 21 | – | 30/− | 71** (63–78) | 78** (64–88) | – |
Song, [28] | Chicago, US | 113 | 49 | 19 | 57 | 24 | 0 | 17 | 0 | 26/− | 58** (49–67) | 66** (57–75) | 74** (66–82) |
Chargari, [37] | Villejuif, France | 45 | 50 | 31.1 | 51 | 13.3 | 4.4 | 51.1 | 8.9 | 26/26.7 | 73*** | 78*** | – |